Methscopolamine
(Synonyms: 甲溴东莨菪碱) 目录号 : GC17825
A muscarinic acetylcholine receptor antagonist
Cas No.:155-41-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Methscopolamine (Pamine) is a muscarinic acetylcholine receptor blocker. Target: mAChRMethylscopolamine is an oral medication used along with other medications to treat peptic ulcers by reducing stomach acid secretion. With the advent of proton pump inhibitors and antihistamine medications it is rarely used for this. It can also be used for stomach or intestinal spasms, to reduce salivation, and to treat motion sickness. From Wikipedia.Methscopolamine (Pamine), an anti-acetylcholine drug, prevented ulcer formation, reduced further volume and acid output but produced a 3-4 fold increase in hexosamine concentration. Tissue (corpus and antrum) hexosamine was moderately reduced by restraint. In the corpus, this was counteracted by methscopolamine but antrum hexosamine was not influenced by this drug. The anti-ulcer property of methscopolamine may be due not only to its effect on acid secretion but also to the rise in gastric mucus concentration that it produced [1].
References:
[1]. Robert, A. and J.E. Nezamis, Effect of an Anti-Acetylcholine Drug, Methscopolamine Bromide, on Ulcer Formation and Gastric Mucus. J Pharm Pharmacol, 1964. 16: p. 690-5.
[2]. Kong Q, et al. Effects of pharmacological treatments on hippocampal NCAM1 and ERK2 expression in epileptic rats with cognitive dysfunction. Oncol Lett. 2016 Sep;12(3):1783-1791.
| Cas No. | 155-41-9 | SDF | |
| 别名 | 甲溴东莨菪碱 | ||
| 化学名 | (1R,2R,4S,5S,7s)-7-((3-hydroxy-2-phenylpropanoyl)oxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide | ||
| Canonical SMILES | O=C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])C([H])([H])O[H])O[C@@]2([H])C([H])([H])[C@]3([H])[N+](C([H])([H])[H])(C([H])([H])[H])[C@@](C2([H])[H])([H])[C@@]4([H])O[C@@]34[H].[Br-] | ||
| 分子式 | C18H24BrNO4 | 分子量 | 398.29 |
| 溶解度 | ≥ 19.9mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5107 mL | 12.5537 mL | 25.1073 mL |
| 5 mM | 0.5021 mL | 2.5107 mL | 5.0215 mL |
| 10 mM | 0.2511 mL | 1.2554 mL | 2.5107 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。